Comparison and evaluation of MPTP-induced subacute and chronic models of Parkinson’s disease in mice

doi:10.12307/2022.231

Abstract

Abstract: BACKGROUND: A mouse model of Parkinson's disease that is inducted by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is one of the widely used animal models that partly reflects the pathogenesis and pathological characteristics of Parkinson’s disease.
OBJECTIVE: To establish subacute and Chronic Parkinson's disease models using MPTP, and to observe the similarities and differences between the two animal models in behavior, histopathology, and changes in related protein levels, and their differences with the clinical symptoms of the disease.
METHODS: Forty C57BL/6J mice were randomized into four groups. In subacute model group, mice were injected with MPTP 25 mg/kg/d intraperitoneally for 7 days. In control group 1, injected with normal saline intraperitoneally; chronic model group, injected with MPTP subcutaneously at 25 mg/kg, and then with probenecid at 250 mg/kg intraperitoneally. In the chronic model group, MPTP+probenecid were injected at an interval of 3.5 days for a total of 10 times to induce a chronic model. In control group 2, mice were injected with probenecid intraperitoneally. The behavioral changes of mice were tested by the rotarod and the pole tests, and the distribution of tyrosine hydroxylase positive cells in the substantia nigra was detected by immunofluorescence staining, and the expression level of tyrosine hydroxylase protein in brain tissue was detected by western blot. The study protocol was approved by the Institutional Animal Care and Use Committee (IACUC) of Guangdong Laboratory Animal Monitoring Institute with AAALAC Certification (No. IACUC 2020137).
RESULTS AND CONCLUSION: In the subacute mouse model, the results of the rotarod test showed that the residence time of the mice on the accelerated rotating rod was significantly reduced compared with the control group 1 (P < 0.05). In the pole test, the time for the mice to move from the top of the pole to the bottom increased significantly compared with the control group 1 (P < 0.05). However, the number of tyrosine hydroxylase positive cells in the substantia nigra and the expression of tyrosine hydroxylase protein were not significantly different from those of the control group 1. In the chronic mouse model, there was no significant difference in the total time of rotarod stay and the pole test compared with the control group 2, but the number of tyrosine hydroxylase positive cells in the substantia nigra and the tyrosine hydroxylase protein expression level were significantly lower than those of the control group 2 (P < 0.05). Therefore, MPTP-induced subacute and chronic Parkinson’s model mouse models show partial similar phenotypes to human Parkinson's disease in sports injuries and pathological changes due to differences in modeling methods, suggesting that it is necessary to select an appropriate animal model based on the study purpose.

Key words: Parkinson’s disease, MPTP, subacute model, chronic model, tyrosine hydroxylase

CLC Number:

Chen Shijian, Li Ge, Zhang Yu, Guan Yalun, Li Xuejiao, Liu Shuhua, Li Yongchao, Li Yunfeng, Gao Jinfeng, Wei Xiaoyue, Zhao Yuhong. Comparison and evaluation of MPTP-induced subacute and chronic models of Parkinson’s disease in mice[J]. Chinese Journal of Tissue Engineering Research, 2022, 26(8): 1247-1252.

Figures/Tables 4

References

[1] REICH SG, SAVITT JM. Parkinson’s Disease. Med Clin North Am. 2019; 103(issue):337-350.
[2] DENG H, WANG P, JANKOVIC J. The genetics of Parkinson disease.Ageing Res Rev. 2018;42:72-85.
[3] ANTONY P, DIEDERICH N, BALLING R. Parkinson’s disease mouse models in translational research. Mamm Genome. 2011;22(7-8):401-419.
[4] RAZA C, ANJUM R, SHAKEEL NUA. Parkinson’s disease: Mechanisms, translational models and management strategies. Life Sci. 2019; 226(issue):77-90.
[5] ARMSTRONG MJ, OKUN MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020;323(issue):548-560.
[6] TAGUCHI T, IKUNO M, YAMAKADO H, et al. Animal Model for Prodromal Parkinson’s Disease. Int J Mol Sci. 2020;21(6):1961.
[7] KIN K, YASUHARA T, KAMEDA M, et al. Animal Models for Parkinson’s Disease Research: Trends in the 2000s. Int J Mol Sci. 2019;20(21):5402.
[8] MORIN N, JOURDAIN V, DI PAOLO T. Modeling dyskinesia in animal models of Parkinson disease. Exp Neurol. 2014;256:105-116.
[9] SUN MF, ZHU YL, ZHOU ZL, et al. Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson’s disease mice: Gut microbiota, glial reaction and TLR4/TNF-α signaling pathway. Brain Behav Immun. 2018;70:48-60.
[10] XIE W, GAO J, JIANG R, et al. Twice subacute MPTP administrations induced time-dependent dopaminergic neurodegeneration and inflammation in midbrain and ileum, as well as gut microbiota disorders in PD mice. Neurotoxicology. 2020;76:200-212.
[11] LIU Y, YUE F, TANG R, et al. Progressive loss of striatal dopamine terminals in MPTP-induced acute parkinsonism in cynomolgus monkeys using vesicular monoamine transporter type 2 PET imaging ([(18)F]AV-133). Neurosci Bull. 2014;30(3):409-416.
[12] WANG L, ZHAI YQ, XU LL, et al. Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice. Exp Neurol. 2014;251:22-29.
[13] MASILAMONI GJ, SMITH Y. Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson’s disease. J Neural Transm (Vienna). 2018;125(3):337-363.
[14] HE X, YANG S, ZHANG R, et al. Smilagenin Protects Dopaminergic Neurons in Chronic MPTP/Probenecid-Lesioned Parkinson’s Disease Models. Front Cell Neurosci. 2019;13:18.
[15] SCHOBER A. 2004. Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP. Cell Tissue Res. 2004;318(1):215-224.
[16] von Bohlen Und Halbach O.Modeling neurodegenerative diseases in vivo review. Neurodegener Dis. 2005;2(6):313-320.
[17] PRZEDBORSKI S. The parkinsonian toxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem. 2001;76(5):1265-1274.
[18] MAIN B, ZHANG M, BRODY K, et al. Type-1 interferons contribute to the neuroinflammatory response and disease progression of the MPTP mouse model of Parkinson’s disease. Glia.2016;64(issue):1590-1604.
[19] VITALI R, CLARKE S. Improved rotorod performance and hyperactivity in mice deficient in a protein repair methyltransferase. Behav Brain Res. 2004;153(1):129-141.
[20] ROZAS G, LABANDEIRA GARCÍA JL. Drug-free evaluation of rat models of parkinsonism and nigral grafts using a new automated rotarod test. Brain Res. 1997;749(2):188-199.
[21] OGAWA N, HIROSE Y, OHARA S, et al. A simple quantitative bradykinesia test in MPTP-treated mice. Res Commun Chem Pathol Pharmacol. 1985;50(3):435-441.
[22] LUCHTMAN DW, SHAO D, SONG C. Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson’s disease. Physiol Behav. 2009;98(1-2):130-138.
[23] PAXINOS G, FRANKLIN K BJ. Paxinos and Franklin’s the Mouse Brain in Stereotaxic Coordinates. Amsterdam : Boston : Elsevier/Academic Press.2013.
[24] KIM A, KOZINA E, KOLACHEV AA, et al.Cooperative synthesis of dopamine by striatal non-dopaminergic neurons as a mechanism of neuroplasticity at parkinsonism. Parkinsonism & Related Disorders. 2018;46(issue):e26-e27.
[25] DE BIE R, CLARKE C, ESPAY A, et al. 2020. Initiation of pharmacological therapy in Parkinson’s disease: when, why, and how. Lancet Neurol. 2020;19(5):452-461.
[26] SIMOLA N, PINNA A, FENU S. Pharmacological therapy of Parkinson’s disease: current options and new avenues. Recent Pat CNS Drug Discov. 2010;5(3):221-238.
[27] RAI SN, SINGH P, VARSHNEY R, et al. Promising drug targets and associated therapeutic interventions in Parkinson’s disease. Neural Regen Res. 2021;16(9):1730-1739.
[28] JACKSON-LEWIS V, PRZEDBORSKI S. Protocol for the MPTP mouse model of Parkinson’s disease. Nat Protoc. 2007;2(issue):141-151.
[29] ROUSSELET E, JOUBERT C, CALLEBERT J, et al. Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of parkinsonian toxin MPTP in mice. Neurobiol Dis. 2003;14(2):218-228.
[30] BEZARD E, GROSS C, BROTCHIE J. Presymptomatic compensation in Parkinson’s disease is not dopamine-mediated. Trends Neurosci. 2003;26(4):215-221.
[31] ZIGMOND M, ABERCROMBIE E, BERGER T, et al. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 1990;13(7):290-296.
[32] ARKADIR D, BERGMAN H, FAHN S. Redundant dopaminergic activity may enable compensatory axonal sprouting in Parkinson disease. Neurology. 2014;82(12):1093-1098.
[33] BERNHEIMER H, BIRKMAYER W, HORNYKIEWICZ O, et al. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973; 20(4):415-455.
[34] NONNEKES J, RUŽICKA E, NIEUWBOER A, et al. Compensation Strategies for Gait Impairments in Parkinson Disease: A Review. JAMA Neurol. 2019;76(6):718-725.
[35] ZHANG QS, HENG Y, MOU Z, et al. Reassessment of subacute MPTP-treated mice as animal model of Parkinson’s disease. Acta Pharmacol Sin. 2017;38(10):1317-1328.
[36] LANGSTON JW. The MPTP Story.J Parkinsons Dis. 2017;7(s1):S11-S19.
[37] HAERI P, MOHAMMADIPOUR A, HEIDARI Z, et al. Neuroprotective effect of crocin on substantia nigra in MPTP-induced Parkinson’s disease model of mice. Anat Sci Int. 2019;94(1):119-127.
[38] LAU Y, TROBOUGH K, CRAMPTON J, et al. Effects of probenecid on striatal dopamine depletion in acute and long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. Gen Pharmacol. 1990; 21(2):181-187.